152 related articles for article (PubMed ID: 29186979)
1. The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.
Slovin SF
Biomark Med; 2017 Dec; 11(12):1149-1159. PubMed ID: 29186979
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in immunotherapy for urological cancer.
Obara W; Kato R; Kato Y; Kanehira M; Takata R
Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
[TBL] [Abstract][Full Text] [Related]
3. [Renaissance of immuno-oncology for urological tumors : Current status].
Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for immunotherapy in genitourinary malignancies.
Slovin SF
Urol Oncol; 2016 Apr; 34(4):205-13. PubMed ID: 25791754
[TBL] [Abstract][Full Text] [Related]
6. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy: new applications in urologic oncology.
Mullane SA; Bellmunt J
Curr Opin Urol; 2016 Nov; 26(6):556-63. PubMed ID: 27584023
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: new applications in urologic oncology.
Hurwitz ME; Sokhn J; Petrylak DP
Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
[TBL] [Abstract][Full Text] [Related]
9. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
Grivas PD; Melas M; Papavassiliou AG
Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
[TBL] [Abstract][Full Text] [Related]
10. Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.
Powles T
Future Oncol; 2017 Aug; 13(18):1581-1583. PubMed ID: 28726491
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
14. Cancer/testis antigens and urological malignancies.
Kulkarni P; Shiraishi T; Rajagopalan K; Kim R; Mooney SM; Getzenberg RH
Nat Rev Urol; 2012 Jun; 9(7):386-96. PubMed ID: 22710665
[TBL] [Abstract][Full Text] [Related]
15. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
17. Candidate immune biomarkers for radioimmunotherapy.
Levy A; Nigro G; Sansonetti PJ; Deutsch E
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):58-68. PubMed ID: 28254528
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
